Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Similar stories

Repurposed drug can induce remission of inflammatory arthritis

Researchers at the Kennedy Institute demonstrate that the drug decitabine can boost regulatory T cell responses.

Major ERC funding awarded to Professor Michael Dustin

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

Small mechanical forces in immune cells measured at unprecedented sensitivity

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Vascular loss shown to be the primary hallmark of aging

New Research from the Kusumbe group at the Kennedy Institute of Rheumatology identifies vascular attrition, marked by pericyte to fibroblast differentiation, as a primary hallmark of aging and highlights organ-specific vascular changes with age.

Immunology preprint reviews launched in Nature Reviews Immunology

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.